•Of the 711 patients enrolled in VALOR, 451 patients were age 60 years and older. Of these, 226 patients were randomized to the vosaroxin/cytarabine arm and 225 patients to the placebo/cytarabine arm.
•For the subgroup analysis, complete remission rates prior to HCT, post-treatment HCT rates, HCT outcomes, and overall survival by treatment arm were assessed.
•Of the 451 patients, HCTs were performed in 91 patients, including 47 patients in the vosaroxin/cytarabine arm and 44 patients in the placebo/cytarabine arm. Of these patients, 27 (57%) achieved a CR prior to transplant in the vosaroxin/cyrarabine arm versus 16 (36%) in the placebo/cytarabine only arm.
•An additional 7 and 6 patients on the respective treatment arms received subsequent therapy, and went on to achieve a CR, resulting in a total of 34 patients (72%) in the vosaroxin/cytarabine arm and 22 patients (50%) in the placebo/cytarabine arm achieving CR prior to transplant.
Need a revised price target from analysts to break past 3.5 - 4.00. Give it a couple of days
Need analyst upgrade/good article and new price target to move towards $5 and beyond. My take is give it a couple of days going into next week.
Worst trade ever SNSS failed miserably. Luckily the guys over at Ultimate Stock Alerts (you’ll find them in Google) helped me out
The updated data will undeniably be accepted by both the FDA and EHA for approval in the treatment of the 60 subgroup. There has been no change in the treatment of AML in 30 plus years.
Sentiment: Strong Buy
it's not just SNSS. The company is okay. Most stocks acting this way, surge in the morning and correct down to nothing or even red by day's end. Stealth bear market going on, imo. Better to wait until 3:45 to see which stocks if any hold up, especially on a sell off day, to decide to go long on something.